ReviewBMJ (Clinical research ed.)2004
Making decisions about benefits and harms of medicines.
Review in BMJ (Clinical research ed.), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Why Oncology Global Safety Teams Should Develop the Safety Section of the Study's Target Product Profile (TPP).Pharmaceutical medicine · 2024Article
- Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.Antibiotics (Basel, Switzerland) · 2022Article
- Evaluation of adverse drug reaction formatting in drug information mobile phone applications.Journal of the Medical Library Association : JMLA · 2022Article
- Pharmacokinetics and Perceptions of Children and Young Adults Using Cannabis for Attention-Deficit/Hyperactivity Disorder and Oppositional Defiant Disorder: Protocol for a Mixed Methods Proof-of-Concept Study.JMIR research protocols · 2021Article
- Adverse drug reactions in drug information databases: does presentation affect interpretation?Journal of the Medical Library Association : JMLA · 2020Article
- A strategy for regulatory action when new adverse effects of a licensed product emerge.Drug safety · 2009Review
- Is There a Tension between Clinical Practice and Reimbursement Policy? The Case of Osteoarthritis Prescribing Practices in Ontario.Healthcare policy = Politiques de sante · 2007Article
- Homeless drug users' awareness and risk perception of peer "take home naloxone" use--a qualitative study.Substance abuse treatment, prevention, and policy · 2006Article
- [Values and preferences of patients: question pending].Atencion primaria · 2005Article
- Over-the-counter medicines.British journal of clinical pharmacology · 2004Article
- Balancing benefits and harms in health care: ethical dimension was not discussed in theme issue.BMJ (Clinical research ed.) · 2004Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.